Table 3

Crude and adjusted rateratios of pneumonia associatedwith current use ofthe different dopamine agonistsrelative to non-current use
Cases Controls Crude Adjusted*
Rate Ratio Rate ratio 95% CI
Number of subjects 1835 16088
Current use† of:
 Any dopamine agonist (%) 269 (14.7) 2,846 (17.7) 0.77 0.87 0.75 – 1.02
  Pramipexole (%) 59 (3.2) 734 (4.6) 0.64 0.76 0.57 – 1.02
  Ropinirole (%) 92 (5.0) 1,095 (6.8) 0.69 0.76 0.60 – 0.97
  Cabergoline (%) 57 (3.1) 397 (2.5) 1.15 1.28 0.94 – 1.75
  Pergolide (%) 43 (2.3) 418 (2.6) 0.90 1.06 0.76 – 1.50
  Other dopamine agonists‡ (%) 23 (1.3) 234 (1.5) 0.74 0.77 0.48 – 1.22

* Adjusted for one another, for current use of other anti-Parkinsonian drugs, including levodopa, selegiline, rasagiline, COMT inhibitors and amantadine, and all factors listed in Table 1.

† Current use refers to a prescription ending after or within 30 days prior to the index date.

‡ Regroups rotigotine, bromocriptine, and lisuride because of low frequencies.

Ernst et al.

Ernst et al. BMC Neurology 2012 12:113   doi:10.1186/1471-2377-12-113

Open Data